BETHLEHEM, Pa., May 02, 2017 -- Furthering its efforts to enhancing patient, clinician and environmental safety, B. Braun Medical Inc. will debut ReadyFor800.com at The Oncology Nursing Society’s Annual Conference, May 4-7 in Denver, Colorado. The new online educational resource will focus on the awareness and implementation of the new hazardous drug safety standard, USP <800>.
“These medications can save the lives of patients, but they also pose risk to our healthcare professionals,” said Tom Sutton, Vice President of Vascular Access Systems at B. Braun. “As one of the leading suppliers of Closed System Transfer Devices (CSTDs) in the United States, B. Braun takes responsibility to help nurses and other healthcare workers proactively protect not only their patients, but also themselves and their coworkers.”
ReadyFor800.com details the risks for healthcare personnel and introduces implementation plans and protocols to ensure the best protection possible from hazardous drug exposure. Supported by expert insight, experience, and recommendations, and told from the pharmacy, nursing and management perspectives, ReadyFor800.com is a comprehensive tool for educating staff and colleagues. It provides a blue print to help implement USP <800> in hospital or outpatient facilities.
At ONS 2017, attendees can visit B. Braun booth #925 to experience ReadyFor800.com. Attendees can gain an understanding of the risks involved in the compounding and administering of hazardous drugs, and discuss the steps required for USP <800> compliance with ONS Connect contributing editor Seth Eisenberg, RN, ASN, OCN®, BMTCN™.
About USP <800>
USP <800> was published on February 1, 2016 with an implementation date of July 1, 2018. The chapter describes practice and quality standards for the handling of hazardous drugs, including transport, storage, preparation, and administration, in healthcare settings to help promote patient safety, worker safety, and environmental protection. USP <800> applies to all healthcare personnel – such as pharmacists, technicians, nurses, physicians, physician assistants, home healthcare workers, veterinarians, and veterinary technicians – as well as all facilities associated with the handling of hazardous drugs.
About B. Braun
B. Braun Medical Inc., a market leader in Closed System Drug Transfer Devices, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. The OnGuard® CSTD from B. Braun is designed to help protect healthcare workers within the pharmacy and specifically during nursing administration of hazardous drugs. OnGuard meets the NIOSH, ASHP, and ONS definitions of a CSTD, along with all proposed USP <800> requirements.
To learn more about B. Braun Medical or OnGuard CSTD, visit www.BBraunUSA.com.
Contact: Jason Ford B. Braun Medical Inc. 610.997.4722 [email protected]


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Instagram Outage Disrupts Thousands of U.S. Users
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Washington Post Publisher Will Lewis Steps Down After Layoffs
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



